Pharmaceuticals

Clearmind Medicine

Clearmind Medicine Inc. Reviews Major Progress in 2025 Drug Development

Clearmind Medicine Completes Recruitment for Alcohol Use Disorder Drug CMND-100 Phase I/IIa Trial Second Group

Clearmind Medicine advances CMND-100 to dosing phase at Hadassah Medical Center

Clearmind Medicine Inc. Receives Consistent Recommendation to Continue CMND-100 Clinical Trial

Clearmind Medicine Inc. Files MEAI Patent Application for Depression in China

Clearmind Medicine Completes First Cohort of Patient Recruitment for CMND-100 Drug Candidate's I/IIa Phase Clinical Trial

Clearmind Medicine released FY2025 Q3 earnings on September 11, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.2458

Clearmind Medicine released FY2025 9 Months Earnings on September 11 (EST), with actual revenue of USD 0 and EPS of USD -25.6125

Clearmind's AUD Treatment Drug Reaches Clinical Trial Milestone

Clearmind Medicine Inc. Updates Clinical Trial Site

Clearmind Medicine Partners with Consulting Firm to Advance Psychedelic Therapies

Clearmind Medicine released FY2025 Semi-Annual Earnings on June 12 (EST) with actual revenue of USD 0 and EPS of USD -15.6008

Clearmind Medicine released FY2025 Q2 earnings on June 12 (EST), actual revenue USD 0, actual EPS USD -0.1556

Clearmind Partners with Government Firm to Advance Psychedelic Therapies

First Patient Enrolled for Clearmind's CMND-100 Clinical Trial

Clearmind Submits International Patent Application for New Anorexia Treatment

Clearmind Hosts Psychedelic Science and Business Symposium

Clearmind Medicine Receives MEAI Treatment Patent Notice

Clearmind Launches First US Clinical Trial for CMND-100

Clearmind Medicine Inc. Launches Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

EKSO Bionics

Antelope Enterprise

Aimei Health Tech

Profusa

Delixy

Urgently

Jyong Biotech

Cemtrex

CID Holdco

ON24

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Clearmind Medicine(CMND.US)